Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Transitional Cell Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm
Transitional Cell Neoplasm

Cancer Family

Transitional Cell Neoplasm

CI-CAN-00000374Explore in graph →

Non-malignant254 active trials5 approved drugs23 evidence items

NCIt: C6783

Overview
Statistics
Survival
Genomics24
Variants & evidence23
Drugs13
Trials753
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (35)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 35 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
· N Engl J Med · 2019 · PMID 31340094 · validated civic_curation pubmed
The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer.
· Cancer Epidemiol Biomarkers Prev · 2005 · PMID 15824158 · validated civic_curation pubmed
Genome sequencing identifies a basis for everolimus sensitivity.
· Science · 2012 · PMID 22923433 · validated civic_curation pubmed
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
· J Clin Oncol · 2016 · PMID 27044931 · validated civic_curation pubmed
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.
· J Clin Oncol · 2015 · PMID 26324363 · validated civic_curation pubmed
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors.
· Clin Cancer Res · 2021 · PMID 34074656 · validated civic_curation pubmed
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.
· Clin Cancer Res · 2020 · PMID 32636318 · validated civic_curation pubmed

Showing 1–25 of 35 publications

← Previous
1
2
Next →

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.

· Cancer Discov · 2023 · PMID 37377403 · validated civic_curation pubmed

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

· Cancer Discov · 2014 · PMID 24625776 · validated civic_curation pubmed

Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.

· J Immunother Cancer · 2015 · PMID 26674132 · validated civic_curation pubmed

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

· Cancer Discov · 2018 · PMID 29848605 · validated civic_curation pubmed

Urothelial carcinoma with an NRF1-BRAF rearrangement and response to targeted therapy.

· Cold Spring Harb Mol Case Stud · 2019 · PMID 31010895 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification.

· Eur Urol · 2015 · PMID 25766722 · validated civic_curation pubmed

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

· Carcinogenesis · 2006 · PMID 16338952 · validated civic_curation pubmed

FGFR3S249C mutation promotes chemoresistance by activating Akt signaling in bladder cancer cells.

· Exp Ther Med · 2019 · PMID 31316618 · validated civic_curation pubmed

Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

· Oncogene · 2009 · PMID 19749790 · validated civic_curation pubmed

Damrauer et al. Nat Commun. 2022

· 2022 · PMID 36333289 · validated cbioportal_study pubmed

Guo et al. Nat Genet 2013

· 2013 · PMID 24121792 · validated cbioportal_study pubmed

Faltas and Prandi, Nature Genetics 2016

· 2016 · PMID 27749842 · validated cbioportal_study pubmed

Van Allen et al. Cancer Discov 2014

· 2014 · PMID 25096233 · validated cbioportal_study pubmed

Iyer, Gopa et al. JCO precision oncology 2024

· 2024 · PMID 39499893 · validated cbioportal_study pubmed

Brendan J et al. Eur Urol Open Sci 2025

· 2025 · PMID 40256659 · validated cbioportal_study pubmed

Pietzak et al. Eur Urol 2019

· 2019 · PMID 30290956 · validated cbioportal_study pubmed

Iyer et al. J Clin Oncol 2013

· 2013 · PMID 23897969 · validated cbioportal_study pubmed